文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
David Lorente
发表
Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
R. Plummer, N. Tunariu, Juanita Lopez, 2015 .